Skip to main content
. 2018 Apr 27;57(18):2647–2655. doi: 10.2169/internalmedicine.0793-18

Table 2.

Demographic and Clinical Characteristics of 9 Patients with Multiple Sclerosis Who Did Not Experience Clinical Nor MRI Exacerbation after Fingolimod Cessation.

Patient No. 11 12 13 14 15 16 17 18 19
Sex F F M F F M M F M
At fingolimod initiation
Disease duration (years) 3 5 6 32 13 15 11 0.5 7
ARR (preceding year) 0 1 0 2 0 0 0 1 0
Clinical course RR RR SP SP SP RR SP RR RR
EDSS 1.0 1.5 5.5 7.0 4.5 0.0 6.5 0.0 0.0
 
During fingolimod therapy
Duration of fingolimod treatment (weeks) 216 56 48 126 182 270 112 243 113
ARR 0.24 0 0 0.41 0 0 0 0 0
EDSS 1.0 1.5 5.5 7.0 4.5 0.0 7.0 0.0 0.0
 
Age at fingolimod cessation (years) 45 33 48 53 49 44 41 23 43
Days from fingolimod cessation to DMF initiation 77 42 35 41 43 72 34 34 30
 
Peripheral blood lymphocyte count (/μL)
At fingolimod cessation 667 701 777 711 720 673 2,628 819 621
4 weeks after fingolimod cessation 939 1,072 1,350 1,339 1,081 807 3,083 1,347 1,198

ARR: annual relapse rate, EDSS: expanded disability status scale, DMF: dimethyl fumarate, MRI: magnetic resonance imaging, RR: relapsing-remitting, SP: secondary progressive, mono: monophasic